5-6 May, 2021
Pietro Scalfaro, our CMO, will present clinical results of our lead compound Vonafexor at the Chronic Hepatitis B Drug Development Summit : “Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B”.
This Summit is the first-ever dedicated digital industry forum dedicated exclusively to the frontier of drug development in Chronic HBV. The two-day program explores the full spectrum of antiviral & immunomodulatory agents being investigated to achieve a functional cure in chronic HBV infection &
Benoît de Chassey gave a talk entitled: “From Virus-Host Interactomes To Drug Discovery” at the Annual Conference of Autophagy DRIVE Consortium (Driving next generation autophagy researchers towards translation) coordinated by Pr Fulvio Reggiori.
December 9-10, 2020
ENYO will attend the 4th edition of I4ID congress. The purpose of this two-day congress is to foster interactions between pharmaceutical industries, research labs, service providers, technology developers, and clinicians, thereby contributing to the development of innovative strategies against infectious diseases in a multidisciplinary approach.
13-16 November, 2020
ENYO Pharma attended the 2020 digital edition of AASLD meeting.
The meeting confirms vonafexor (EYP001, FXRag) unique positioning for HBV and possible differentiated profile for NASH with ph2s on track to deliver in H1 2021.
We also presented a poster describing a novel small molecule modulating the mitochondrial NEET proteins that improves inflammation and fibrosis in liver and kidneys of NASH mice :
ENYO Pharma is present at the digital Kidney Week 2020 organized by the ASN with a poster. ASN has been honored to host the world’s premier meeting in nephrology for 50+ years, which has been “Reimagined” as a fully digital meeting.
“A novel small molecule modulating the mitochondrial NEET proteins improves inflammation and fibrosis in kidneys of NASH mice”